nodes	percent_of_prediction	percent_of_DWPC	metapath
Regorafenib—ABCG2—Cladribine—multiple sclerosis	0.0711	0.157	CbGbCtD
Regorafenib—ABCG2—Mitoxantrone—multiple sclerosis	0.0519	0.114	CbGbCtD
Regorafenib—ABCG2—Dexamethasone—multiple sclerosis	0.0269	0.0593	CbGbCtD
Regorafenib—ABCB1—Methylprednisolone—multiple sclerosis	0.0256	0.0565	CbGbCtD
Regorafenib—CYP3A4—Fingolimod—multiple sclerosis	0.0238	0.0526	CbGbCtD
Regorafenib—ABCG2—Methotrexate—multiple sclerosis	0.0216	0.0477	CbGbCtD
Regorafenib—CYP2C19—Prednisone—multiple sclerosis	0.0193	0.0425	CbGbCtD
Regorafenib—CYP2B6—Dexamethasone—multiple sclerosis	0.0189	0.0417	CbGbCtD
Regorafenib—ABCB1—Mitoxantrone—multiple sclerosis	0.0187	0.0412	CbGbCtD
Regorafenib—ABCB1—Betamethasone—multiple sclerosis	0.0167	0.0368	CbGbCtD
Regorafenib—ABCB1—Prednisolone—multiple sclerosis	0.0165	0.0363	CbGbCtD
Regorafenib—ABCB1—Prednisone—multiple sclerosis	0.0155	0.0343	CbGbCtD
Regorafenib—CYP3A4—Methylprednisolone—multiple sclerosis	0.0154	0.0339	CbGbCtD
Regorafenib—CYP2C8—Dexamethasone—multiple sclerosis	0.0143	0.0316	CbGbCtD
Regorafenib—CYP2C19—Dexamethasone—multiple sclerosis	0.012	0.0265	CbGbCtD
Regorafenib—CYP3A4—Triamcinolone—multiple sclerosis	0.0116	0.0257	CbGbCtD
Regorafenib—CYP3A4—Mitoxantrone—multiple sclerosis	0.0112	0.0247	CbGbCtD
Regorafenib—CYP2C9—Dexamethasone—multiple sclerosis	0.01	0.022	CbGbCtD
Regorafenib—CYP3A4—Betamethasone—multiple sclerosis	0.00999	0.022	CbGbCtD
Regorafenib—CYP3A4—Prednisolone—multiple sclerosis	0.00986	0.0217	CbGbCtD
Regorafenib—ABCB1—Dexamethasone—multiple sclerosis	0.0097	0.0214	CbGbCtD
Regorafenib—CYP3A4—Prednisone—multiple sclerosis	0.00931	0.0205	CbGbCtD
Regorafenib—ABCB1—Methotrexate—multiple sclerosis	0.0078	0.0172	CbGbCtD
Regorafenib—CYP3A4—Dexamethasone—multiple sclerosis	0.00581	0.0128	CbGbCtD
Regorafenib—DDR2—retina—multiple sclerosis	0.0032	0.0311	CbGeAlD
Regorafenib—NTRK1—midbrain—multiple sclerosis	0.00285	0.0276	CbGeAlD
Regorafenib—EPHX2—retina—multiple sclerosis	0.00216	0.021	CbGeAlD
Regorafenib—DDR2—spinal cord—multiple sclerosis	0.00206	0.02	CbGeAlD
Regorafenib—DDR2—nervous system—multiple sclerosis	0.00174	0.0169	CbGeAlD
Regorafenib—FGFR2—brainstem—multiple sclerosis	0.0017	0.0165	CbGeAlD
Regorafenib—DDR2—central nervous system—multiple sclerosis	0.00167	0.0163	CbGeAlD
Regorafenib—MAPK11—nervous system—multiple sclerosis	0.00165	0.016	CbGeAlD
Regorafenib—DDR2—cerebellum—multiple sclerosis	0.00164	0.0159	CbGeAlD
Regorafenib—MAPK11—central nervous system—multiple sclerosis	0.00159	0.0154	CbGeAlD
Regorafenib—RAF1—brainstem—multiple sclerosis	0.00156	0.0152	CbGeAlD
Regorafenib—MAPK11—cerebellum—multiple sclerosis	0.00155	0.0151	CbGeAlD
Regorafenib—FLT1—retina—multiple sclerosis	0.00152	0.0147	CbGeAlD
Regorafenib—BRAF—midbrain—multiple sclerosis	0.0015	0.0145	CbGeAlD
Regorafenib—FGFR1—medulla oblongata—multiple sclerosis	0.00139	0.0135	CbGeAlD
Regorafenib—DDR2—brain—multiple sclerosis	0.00133	0.0129	CbGeAlD
Regorafenib—KDR—retina—multiple sclerosis	0.00128	0.0124	CbGeAlD
Regorafenib—FGFR1—midbrain—multiple sclerosis	0.00127	0.0123	CbGeAlD
Regorafenib—MAPK11—brain—multiple sclerosis	0.00126	0.0122	CbGeAlD
Regorafenib—RET—medulla oblongata—multiple sclerosis	0.00124	0.0121	CbGeAlD
Regorafenib—FGFR1—spinal cord—multiple sclerosis	0.00124	0.012	CbGeAlD
Regorafenib—KIT—brainstem—multiple sclerosis	0.00118	0.0114	CbGeAlD
Regorafenib—BRAF—cerebellum—multiple sclerosis	0.00116	0.0112	CbGeAlD
Regorafenib—RET—midbrain—multiple sclerosis	0.00114	0.011	CbGeAlD
Regorafenib—TEK—medulla oblongata—multiple sclerosis	0.00113	0.011	CbGeAlD
Regorafenib—RET—spinal cord—multiple sclerosis	0.00111	0.0108	CbGeAlD
Regorafenib—EPHX2—cerebellum—multiple sclerosis	0.00111	0.0107	CbGeAlD
Regorafenib—FLT1—medulla oblongata—multiple sclerosis	0.0011	0.0106	CbGeAlD
Regorafenib—RAF1—medulla oblongata—multiple sclerosis	0.00109	0.0106	CbGeAlD
Regorafenib—FGFR2—spinal cord—multiple sclerosis	0.00105	0.0102	CbGeAlD
Regorafenib—TEK—midbrain—multiple sclerosis	0.00104	0.0101	CbGeAlD
Regorafenib—ABL1—brainstem—multiple sclerosis	0.00103	0.00995	CbGeAlD
Regorafenib—TEK—spinal cord—multiple sclerosis	0.00101	0.00982	CbGeAlD
Regorafenib—FLT1—midbrain—multiple sclerosis	0.001	0.00973	CbGeAlD
Regorafenib—RAF1—midbrain—multiple sclerosis	0.000996	0.00967	CbGeAlD
Regorafenib—ABL1—retina—multiple sclerosis	0.000989	0.0096	CbGeAlD
Regorafenib—FGFR1—cerebellum—multiple sclerosis	0.000983	0.00955	CbGeAlD
Regorafenib—FLT1—spinal cord—multiple sclerosis	0.000978	0.00949	CbGeAlD
Regorafenib—RAF1—spinal cord—multiple sclerosis	0.000972	0.00944	CbGeAlD
Regorafenib—BRAF—brain—multiple sclerosis	0.000939	0.00912	CbGeAlD
Regorafenib—RET—nervous system—multiple sclerosis	0.000935	0.00908	CbGeAlD
Regorafenib—KDR—medulla oblongata—multiple sclerosis	0.000927	0.009	CbGeAlD
Regorafenib—PDGFRA—spinal cord—multiple sclerosis	0.000916	0.00889	CbGeAlD
Regorafenib—RET—central nervous system—multiple sclerosis	0.0009	0.00874	CbGeAlD
Regorafenib—EPHX2—brain—multiple sclerosis	0.000898	0.00872	CbGeAlD
Regorafenib—FGFR2—nervous system—multiple sclerosis	0.000889	0.00863	CbGeAlD
Regorafenib—RET—cerebellum—multiple sclerosis	0.00088	0.00854	CbGeAlD
Regorafenib—EPHA2—nervous system—multiple sclerosis	0.000873	0.00848	CbGeAlD
Regorafenib—FGFR2—central nervous system—multiple sclerosis	0.000856	0.00831	CbGeAlD
Regorafenib—TEK—nervous system—multiple sclerosis	0.000852	0.00827	CbGeAlD
Regorafenib—KDR—midbrain—multiple sclerosis	0.000847	0.00822	CbGeAlD
Regorafenib—EPHA2—central nervous system—multiple sclerosis	0.000841	0.00816	CbGeAlD
Regorafenib—FGFR2—cerebellum—multiple sclerosis	0.000836	0.00812	CbGeAlD
Regorafenib—KDR—spinal cord—multiple sclerosis	0.000826	0.00802	CbGeAlD
Regorafenib—FLT1—nervous system—multiple sclerosis	0.000824	0.008	CbGeAlD
Regorafenib—KIT—medulla oblongata—multiple sclerosis	0.000821	0.00797	CbGeAlD
Regorafenib—TEK—central nervous system—multiple sclerosis	0.00082	0.00796	CbGeAlD
Regorafenib—RAF1—nervous system—multiple sclerosis	0.000819	0.00795	CbGeAlD
Regorafenib—FLT4—brain—multiple sclerosis	0.00081	0.00786	CbGeAlD
Regorafenib—PDGFRB—medulla oblongata—multiple sclerosis	0.000802	0.00779	CbGeAlD
Regorafenib—TEK—cerebellum—multiple sclerosis	0.000802	0.00778	CbGeAlD
Regorafenib—FGFR1—brain—multiple sclerosis	0.000799	0.00776	CbGeAlD
Regorafenib—FLT1—central nervous system—multiple sclerosis	0.000793	0.0077	CbGeAlD
Regorafenib—RAF1—central nervous system—multiple sclerosis	0.000788	0.00765	CbGeAlD
Regorafenib—FLT1—cerebellum—multiple sclerosis	0.000775	0.00753	CbGeAlD
Regorafenib—PDGFRA—nervous system—multiple sclerosis	0.000772	0.00749	CbGeAlD
Regorafenib—RAF1—cerebellum—multiple sclerosis	0.000771	0.00748	CbGeAlD
Regorafenib—KIT—midbrain—multiple sclerosis	0.000751	0.00729	CbGeAlD
Regorafenib—PDGFRA—central nervous system—multiple sclerosis	0.000743	0.00721	CbGeAlD
Regorafenib—PDGFRB—midbrain—multiple sclerosis	0.000733	0.00712	CbGeAlD
Regorafenib—KIT—spinal cord—multiple sclerosis	0.000732	0.00711	CbGeAlD
Regorafenib—PDGFRA—cerebellum—multiple sclerosis	0.000726	0.00705	CbGeAlD
Regorafenib—PDGFRB—spinal cord—multiple sclerosis	0.000715	0.00694	CbGeAlD
Regorafenib—ABL1—medulla oblongata—multiple sclerosis	0.000715	0.00694	CbGeAlD
Regorafenib—RET—brain—multiple sclerosis	0.000715	0.00694	CbGeAlD
Regorafenib—KDR—nervous system—multiple sclerosis	0.000696	0.00676	CbGeAlD
Regorafenib—FGFR2—brain—multiple sclerosis	0.000679	0.00659	CbGeAlD
Regorafenib—KDR—central nervous system—multiple sclerosis	0.00067	0.00651	CbGeAlD
Regorafenib—EPHA2—brain—multiple sclerosis	0.000668	0.00648	CbGeAlD
Regorafenib—KDR—cerebellum—multiple sclerosis	0.000655	0.00636	CbGeAlD
Regorafenib—ABL1—midbrain—multiple sclerosis	0.000653	0.00634	CbGeAlD
Regorafenib—TEK—brain—multiple sclerosis	0.000651	0.00632	CbGeAlD
Regorafenib—ABL1—spinal cord—multiple sclerosis	0.000637	0.00619	CbGeAlD
Regorafenib—FLT1—brain—multiple sclerosis	0.00063	0.00611	CbGeAlD
Regorafenib—RAF1—brain—multiple sclerosis	0.000626	0.00608	CbGeAlD
Regorafenib—KIT—nervous system—multiple sclerosis	0.000617	0.00599	CbGeAlD
Regorafenib—PDGFRB—nervous system—multiple sclerosis	0.000603	0.00585	CbGeAlD
Regorafenib—KIT—central nervous system—multiple sclerosis	0.000594	0.00577	CbGeAlD
Regorafenib—PDGFRA—brain—multiple sclerosis	0.00059	0.00573	CbGeAlD
Regorafenib—KIT—cerebellum—multiple sclerosis	0.000581	0.00564	CbGeAlD
Regorafenib—PDGFRB—central nervous system—multiple sclerosis	0.00058	0.00563	CbGeAlD
Regorafenib—PDGFRB—cerebellum—multiple sclerosis	0.000567	0.00551	CbGeAlD
Regorafenib—Headache—Fingolimod—multiple sclerosis	0.000555	0.00298	CcSEcCtD
Regorafenib—Erythema multiforme—Azathioprine—multiple sclerosis	0.000543	0.00292	CcSEcCtD
Regorafenib—Neutropenia—Mitoxantrone—multiple sclerosis	0.000543	0.00292	CcSEcCtD
Regorafenib—ABL1—nervous system—multiple sclerosis	0.000537	0.00521	CbGeAlD
Regorafenib—KDR—brain—multiple sclerosis	0.000532	0.00517	CbGeAlD
Regorafenib—Weight decreased—Mitoxantrone—multiple sclerosis	0.000525	0.00282	CcSEcCtD
Regorafenib—Proteinuria—Methotrexate—multiple sclerosis	0.000525	0.00282	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Cladribine—multiple sclerosis	0.00052	0.0028	CcSEcCtD
Regorafenib—Mediastinal disorder—Azathioprine—multiple sclerosis	0.000518	0.00278	CcSEcCtD
Regorafenib—Protein urine present—Methotrexate—multiple sclerosis	0.000517	0.00278	CcSEcCtD
Regorafenib—ABL1—central nervous system—multiple sclerosis	0.000517	0.00502	CbGeAlD
Regorafenib—Musculoskeletal stiffness—Methotrexate—multiple sclerosis	0.000514	0.00276	CcSEcCtD
Regorafenib—Acute coronary syndrome—Mitoxantrone—multiple sclerosis	0.00051	0.00274	CcSEcCtD
Regorafenib—Alopecia—Azathioprine—multiple sclerosis	0.000508	0.00273	CcSEcCtD
Regorafenib—Myocardial infarction—Mitoxantrone—multiple sclerosis	0.000507	0.00273	CcSEcCtD
Regorafenib—Hyperbilirubinaemia—Methotrexate—multiple sclerosis	0.000507	0.00272	CcSEcCtD
Regorafenib—ABL1—cerebellum—multiple sclerosis	0.000505	0.00491	CbGeAlD
Regorafenib—Dry skin—Prednisolone—multiple sclerosis	0.000505	0.00271	CcSEcCtD
Regorafenib—Stomatitis—Mitoxantrone—multiple sclerosis	0.000505	0.00271	CcSEcCtD
Regorafenib—Infection—Cladribine—multiple sclerosis	0.000499	0.00268	CcSEcCtD
Regorafenib—Hyperuricaemia—Methotrexate—multiple sclerosis	0.000497	0.00267	CcSEcCtD
Regorafenib—Nervous system disorder—Cladribine—multiple sclerosis	0.000493	0.00265	CcSEcCtD
Regorafenib—Thrombocytopenia—Cladribine—multiple sclerosis	0.000492	0.00264	CcSEcCtD
Regorafenib—Skin disorder—Cladribine—multiple sclerosis	0.000488	0.00262	CcSEcCtD
Regorafenib—KIT—brain—multiple sclerosis	0.000472	0.00458	CbGeAlD
Regorafenib—Blood uric acid increased—Methotrexate—multiple sclerosis	0.000469	0.00252	CcSEcCtD
Regorafenib—Haemoglobin—Mitoxantrone—multiple sclerosis	0.000467	0.00251	CcSEcCtD
Regorafenib—Haemorrhage—Mitoxantrone—multiple sclerosis	0.000465	0.0025	CcSEcCtD
Regorafenib—Anaemia—Azathioprine—multiple sclerosis	0.000462	0.00249	CcSEcCtD
Regorafenib—PDGFRB—brain—multiple sclerosis	0.000461	0.00447	CbGeAlD
Regorafenib—ABCG2—medulla oblongata—multiple sclerosis	0.000451	0.00438	CbGeAlD
Regorafenib—Leukopenia—Azathioprine—multiple sclerosis	0.000448	0.00241	CcSEcCtD
Regorafenib—Alanine aminotransferase increased—Methylprednisolone—multiple sclerosis	0.000446	0.0024	CcSEcCtD
Regorafenib—Decreased appetite—Cladribine—multiple sclerosis	0.000437	0.00235	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Cladribine—multiple sclerosis	0.000434	0.00233	CcSEcCtD
Regorafenib—Fatigue—Cladribine—multiple sclerosis	0.000433	0.00233	CcSEcCtD
Regorafenib—Pain—Cladribine—multiple sclerosis	0.000429	0.00231	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—multiple sclerosis	0.000423	0.00227	CcSEcCtD
Regorafenib—Dry skin—Dexamethasone—multiple sclerosis	0.000421	0.00226	CcSEcCtD
Regorafenib—Dry skin—Betamethasone—multiple sclerosis	0.000421	0.00226	CcSEcCtD
Regorafenib—Acute coronary syndrome—Prednisolone—multiple sclerosis	0.000419	0.00225	CcSEcCtD
Regorafenib—Hypokalaemia—Betamethasone—multiple sclerosis	0.000418	0.00225	CcSEcCtD
Regorafenib—Hypokalaemia—Dexamethasone—multiple sclerosis	0.000418	0.00225	CcSEcCtD
Regorafenib—Neoplasm—Methotrexate—multiple sclerosis	0.000417	0.00224	CcSEcCtD
Regorafenib—Myocardial infarction—Prednisolone—multiple sclerosis	0.000416	0.00224	CcSEcCtD
Regorafenib—ABCG2—midbrain—multiple sclerosis	0.000412	0.004	CbGeAlD
Regorafenib—Gastrointestinal pain—Cladribine—multiple sclerosis	0.000411	0.00221	CcSEcCtD
Regorafenib—Alopecia—Mitoxantrone—multiple sclerosis	0.000411	0.00221	CcSEcCtD
Regorafenib—ABL1—brain—multiple sclerosis	0.000411	0.00399	CbGeAlD
Regorafenib—Infection—Azathioprine—multiple sclerosis	0.000406	0.00218	CcSEcCtD
Regorafenib—ABCG2—spinal cord—multiple sclerosis	0.000402	0.0039	CbGeAlD
Regorafenib—Thrombocytopenia—Azathioprine—multiple sclerosis	0.0004	0.00215	CcSEcCtD
Regorafenib—Abdominal pain—Cladribine—multiple sclerosis	0.000397	0.00213	CcSEcCtD
Regorafenib—Body temperature increased—Cladribine—multiple sclerosis	0.000397	0.00213	CcSEcCtD
Regorafenib—Skin disorder—Azathioprine—multiple sclerosis	0.000397	0.00213	CcSEcCtD
Regorafenib—Infestation—Methylprednisolone—multiple sclerosis	0.00039	0.00209	CcSEcCtD
Regorafenib—Infestation NOS—Methylprednisolone—multiple sclerosis	0.00039	0.00209	CcSEcCtD
Regorafenib—Acute coronary syndrome—Triamcinolone—multiple sclerosis	0.000385	0.00207	CcSEcCtD
Regorafenib—Acute coronary syndrome—Methylprednisolone—multiple sclerosis	0.000384	0.00206	CcSEcCtD
Regorafenib—Haemoglobin—Prednisolone—multiple sclerosis	0.000383	0.00206	CcSEcCtD
Regorafenib—Myocardial infarction—Triamcinolone—multiple sclerosis	0.000383	0.00206	CcSEcCtD
Regorafenib—Myocardial infarction—Methylprednisolone—multiple sclerosis	0.000382	0.00205	CcSEcCtD
Regorafenib—Haemorrhage—Prednisolone—multiple sclerosis	0.000381	0.00205	CcSEcCtD
Regorafenib—Anaemia—Mitoxantrone—multiple sclerosis	0.000374	0.00201	CcSEcCtD
Regorafenib—Dry skin—Prednisone—multiple sclerosis	0.000367	0.00197	CcSEcCtD
Regorafenib—Hypokalaemia—Prednisone—multiple sclerosis	0.000364	0.00196	CcSEcCtD
Regorafenib—Leukopenia—Mitoxantrone—multiple sclerosis	0.000362	0.00195	CcSEcCtD
Regorafenib—Asthenia—Cladribine—multiple sclerosis	0.00036	0.00194	CcSEcCtD
Regorafenib—Weight decreased—Betamethasone—multiple sclerosis	0.00036	0.00193	CcSEcCtD
Regorafenib—Weight decreased—Dexamethasone—multiple sclerosis	0.00036	0.00193	CcSEcCtD
Regorafenib—Alanine aminotransferase increased—Prednisone—multiple sclerosis	0.000353	0.0019	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Azathioprine—multiple sclerosis	0.000353	0.00189	CcSEcCtD
Regorafenib—Haemoglobin—Triamcinolone—multiple sclerosis	0.000352	0.00189	CcSEcCtD
Regorafenib—Haemoglobin—Methylprednisolone—multiple sclerosis	0.000352	0.00189	CcSEcCtD
Regorafenib—Haemorrhage—Triamcinolone—multiple sclerosis	0.000351	0.00188	CcSEcCtD
Regorafenib—Haemorrhage—Methylprednisolone—multiple sclerosis	0.00035	0.00188	CcSEcCtD
Regorafenib—Acute coronary syndrome—Betamethasone—multiple sclerosis	0.000349	0.00188	CcSEcCtD
Regorafenib—Acute coronary syndrome—Dexamethasone—multiple sclerosis	0.000349	0.00188	CcSEcCtD
Regorafenib—Hypertension—Mitoxantrone—multiple sclerosis	0.000349	0.00188	CcSEcCtD
Regorafenib—Myocardial infarction—Dexamethasone—multiple sclerosis	0.000347	0.00187	CcSEcCtD
Regorafenib—Myocardial infarction—Betamethasone—multiple sclerosis	0.000347	0.00187	CcSEcCtD
Regorafenib—Connective tissue disorder—Methylprednisolone—multiple sclerosis	0.000344	0.00185	CcSEcCtD
Regorafenib—Diarrhoea—Cladribine—multiple sclerosis	0.000344	0.00185	CcSEcCtD
Regorafenib—Gastrointestinal pain—Azathioprine—multiple sclerosis	0.000334	0.00179	CcSEcCtD
Regorafenib—Infection—Mitoxantrone—multiple sclerosis	0.000328	0.00176	CcSEcCtD
Regorafenib—Cardiac disorder—Methylprednisolone—multiple sclerosis	0.000325	0.00174	CcSEcCtD
Regorafenib—Neutropenia—Prednisone—multiple sclerosis	0.000324	0.00174	CcSEcCtD
Regorafenib—Thrombocytopenia—Mitoxantrone—multiple sclerosis	0.000323	0.00174	CcSEcCtD
Regorafenib—Abdominal pain—Azathioprine—multiple sclerosis	0.000323	0.00173	CcSEcCtD
Regorafenib—Body temperature increased—Azathioprine—multiple sclerosis	0.000323	0.00173	CcSEcCtD
Regorafenib—Skin disorder—Mitoxantrone—multiple sclerosis	0.000321	0.00172	CcSEcCtD
Regorafenib—Haemoglobin—Betamethasone—multiple sclerosis	0.00032	0.00172	CcSEcCtD
Regorafenib—Haemoglobin—Dexamethasone—multiple sclerosis	0.00032	0.00172	CcSEcCtD
Regorafenib—Vomiting—Cladribine—multiple sclerosis	0.000319	0.00172	CcSEcCtD
Regorafenib—ABCG2—cerebellum—multiple sclerosis	0.000319	0.00309	CbGeAlD
Regorafenib—Haemorrhage—Betamethasone—multiple sclerosis	0.000318	0.00171	CcSEcCtD
Regorafenib—Haemorrhage—Dexamethasone—multiple sclerosis	0.000318	0.00171	CcSEcCtD
Regorafenib—Angiopathy—Methylprednisolone—multiple sclerosis	0.000317	0.00171	CcSEcCtD
Regorafenib—Rash—Cladribine—multiple sclerosis	0.000317	0.0017	CcSEcCtD
Regorafenib—Dermatitis—Cladribine—multiple sclerosis	0.000316	0.0017	CcSEcCtD
Regorafenib—Mediastinal disorder—Methylprednisolone—multiple sclerosis	0.000315	0.00169	CcSEcCtD
Regorafenib—Headache—Cladribine—multiple sclerosis	0.000315	0.00169	CcSEcCtD
Regorafenib—Weight decreased—Prednisone—multiple sclerosis	0.000313	0.00168	CcSEcCtD
Regorafenib—CYP2B6—nervous system—multiple sclerosis	0.000313	0.00303	CbGeAlD
Regorafenib—ABCB1—retina—multiple sclerosis	0.000308	0.00299	CbGeAlD
Regorafenib—Malnutrition—Methylprednisolone—multiple sclerosis	0.000304	0.00164	CcSEcCtD
Regorafenib—Acute coronary syndrome—Prednisone—multiple sclerosis	0.000304	0.00163	CcSEcCtD
Regorafenib—Myocardial infarction—Prednisone—multiple sclerosis	0.000302	0.00163	CcSEcCtD
Regorafenib—Toxic epidermal necrolysis—Methotrexate—multiple sclerosis	0.000301	0.00162	CcSEcCtD
Regorafenib—CYP2B6—central nervous system—multiple sclerosis	0.000301	0.00292	CbGeAlD
Regorafenib—Nausea—Cladribine—multiple sclerosis	0.000298	0.0016	CcSEcCtD
Regorafenib—Angiopathy—Dexamethasone—multiple sclerosis	0.000289	0.00155	CcSEcCtD
Regorafenib—Angiopathy—Betamethasone—multiple sclerosis	0.000289	0.00155	CcSEcCtD
Regorafenib—Decreased appetite—Mitoxantrone—multiple sclerosis	0.000287	0.00154	CcSEcCtD
Regorafenib—Hypertension—Prednisolone—multiple sclerosis	0.000286	0.00154	CcSEcCtD
Regorafenib—Fatigue—Mitoxantrone—multiple sclerosis	0.000285	0.00153	CcSEcCtD
Regorafenib—Pain—Mitoxantrone—multiple sclerosis	0.000282	0.00152	CcSEcCtD
Regorafenib—Alopecia—Betamethasone—multiple sclerosis	0.000281	0.00151	CcSEcCtD
Regorafenib—Alopecia—Dexamethasone—multiple sclerosis	0.000281	0.00151	CcSEcCtD
Regorafenib—Diarrhoea—Azathioprine—multiple sclerosis	0.000279	0.0015	CcSEcCtD
Regorafenib—Haemoglobin—Prednisone—multiple sclerosis	0.000278	0.0015	CcSEcCtD
Regorafenib—Haemorrhage—Prednisone—multiple sclerosis	0.000277	0.00149	CcSEcCtD
Regorafenib—Connective tissue disorder—Prednisone—multiple sclerosis	0.000272	0.00146	CcSEcCtD
Regorafenib—Neutropenia—Methotrexate—multiple sclerosis	0.00027	0.00145	CcSEcCtD
Regorafenib—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.00027	0.00145	CcSEcCtD
Regorafenib—CYP2C8—brain—multiple sclerosis	0.000266	0.00259	CbGeAlD
Regorafenib—Hypertension—Triamcinolone—multiple sclerosis	0.000263	0.00142	CcSEcCtD
Regorafenib—Hypertension—Methylprednisolone—multiple sclerosis	0.000263	0.00141	CcSEcCtD
Regorafenib—Abdominal pain—Mitoxantrone—multiple sclerosis	0.000261	0.0014	CcSEcCtD
Regorafenib—Body temperature increased—Mitoxantrone—multiple sclerosis	0.000261	0.0014	CcSEcCtD
Regorafenib—Vomiting—Azathioprine—multiple sclerosis	0.00026	0.0014	CcSEcCtD
Regorafenib—ABCG2—brain—multiple sclerosis	0.000259	0.00251	CbGeAlD
Regorafenib—Infestation NOS—Methotrexate—multiple sclerosis	0.000258	0.00139	CcSEcCtD
Regorafenib—Infestation—Methotrexate—multiple sclerosis	0.000258	0.00139	CcSEcCtD
Regorafenib—Rash—Azathioprine—multiple sclerosis	0.000257	0.00138	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000257	0.00138	CcSEcCtD
Regorafenib—Dermatitis—Azathioprine—multiple sclerosis	0.000257	0.00138	CcSEcCtD
Regorafenib—Headache—Azathioprine—multiple sclerosis	0.000256	0.00137	CcSEcCtD
Regorafenib—Stevens-Johnson syndrome—Methotrexate—multiple sclerosis	0.000256	0.00137	CcSEcCtD
Regorafenib—Dry mouth—Triamcinolone—multiple sclerosis	0.000254	0.00137	CcSEcCtD
Regorafenib—Stomatitis—Methotrexate—multiple sclerosis	0.000251	0.00135	CcSEcCtD
Regorafenib—Angiopathy—Prednisone—multiple sclerosis	0.000251	0.00135	CcSEcCtD
Regorafenib—Infection—Triamcinolone—multiple sclerosis	0.000247	0.00133	CcSEcCtD
Regorafenib—Infection—Methylprednisolone—multiple sclerosis	0.000247	0.00133	CcSEcCtD
Regorafenib—Alopecia—Prednisone—multiple sclerosis	0.000245	0.00132	CcSEcCtD
Regorafenib—Hepatobiliary disease—Methotrexate—multiple sclerosis	0.000244	0.00131	CcSEcCtD
Regorafenib—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000244	0.00131	CcSEcCtD
Regorafenib—Nausea—Azathioprine—multiple sclerosis	0.000243	0.0013	CcSEcCtD
Regorafenib—Skin disorder—Methylprednisolone—multiple sclerosis	0.000241	0.0013	CcSEcCtD
Regorafenib—Malnutrition—Prednisone—multiple sclerosis	0.000241	0.0013	CcSEcCtD
Regorafenib—Hypertension—Betamethasone—multiple sclerosis	0.000239	0.00128	CcSEcCtD
Regorafenib—Hypertension—Dexamethasone—multiple sclerosis	0.000239	0.00128	CcSEcCtD
Regorafenib—CYP2B6—brain—multiple sclerosis	0.000239	0.00232	CbGeAlD
Regorafenib—Asthenia—Mitoxantrone—multiple sclerosis	0.000237	0.00127	CcSEcCtD
Regorafenib—CYP3A4—nervous system—multiple sclerosis	0.000236	0.00229	CbGeAlD
Regorafenib—Haemoglobin—Methotrexate—multiple sclerosis	0.000233	0.00125	CcSEcCtD
Regorafenib—Pain—Prednisolone—multiple sclerosis	0.000232	0.00124	CcSEcCtD
Regorafenib—Haemorrhage—Methotrexate—multiple sclerosis	0.000231	0.00124	CcSEcCtD
Regorafenib—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000229	0.00123	CcSEcCtD
Regorafenib—CYP3A4—central nervous system—multiple sclerosis	0.000227	0.00221	CbGeAlD
Regorafenib—Urethral disorder—Methotrexate—multiple sclerosis	0.000227	0.00122	CcSEcCtD
Regorafenib—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000226	0.00121	CcSEcCtD
Regorafenib—Infection—Dexamethasone—multiple sclerosis	0.000224	0.00121	CcSEcCtD
Regorafenib—Infection—Betamethasone—multiple sclerosis	0.000224	0.00121	CcSEcCtD
Regorafenib—Anaemia—Prednisone—multiple sclerosis	0.000223	0.0012	CcSEcCtD
Regorafenib—ABCB1—medulla oblongata—multiple sclerosis	0.000222	0.00216	CbGeAlD
Regorafenib—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000222	0.00119	CcSEcCtD
Regorafenib—Nervous system disorder—Betamethasone—multiple sclerosis	0.000222	0.00119	CcSEcCtD
Regorafenib—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000221	0.00119	CcSEcCtD
Regorafenib—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000221	0.00119	CcSEcCtD
Regorafenib—Erythema multiforme—Methotrexate—multiple sclerosis	0.000219	0.00118	CcSEcCtD
Regorafenib—Cardiac disorder—Methotrexate—multiple sclerosis	0.000215	0.00115	CcSEcCtD
Regorafenib—Fatigue—Triamcinolone—multiple sclerosis	0.000215	0.00115	CcSEcCtD
Regorafenib—Fatigue—Methylprednisolone—multiple sclerosis	0.000214	0.00115	CcSEcCtD
Regorafenib—Pain—Triamcinolone—multiple sclerosis	0.000213	0.00114	CcSEcCtD
Regorafenib—Angiopathy—Methotrexate—multiple sclerosis	0.00021	0.00113	CcSEcCtD
Regorafenib—Vomiting—Mitoxantrone—multiple sclerosis	0.00021	0.00113	CcSEcCtD
Regorafenib—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000209	0.00112	CcSEcCtD
Regorafenib—Hypertension—Prednisone—multiple sclerosis	0.000208	0.00112	CcSEcCtD
Regorafenib—Rash—Mitoxantrone—multiple sclerosis	0.000208	0.00112	CcSEcCtD
Regorafenib—Dermatitis—Mitoxantrone—multiple sclerosis	0.000208	0.00112	CcSEcCtD
Regorafenib—Headache—Mitoxantrone—multiple sclerosis	0.000207	0.00111	CcSEcCtD
Regorafenib—Alopecia—Methotrexate—multiple sclerosis	0.000205	0.0011	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000204	0.0011	CcSEcCtD
Regorafenib—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000203	0.00109	CcSEcCtD
Regorafenib—ABCB1—midbrain—multiple sclerosis	0.000203	0.00197	CbGeAlD
Regorafenib—Malnutrition—Methotrexate—multiple sclerosis	0.000202	0.00108	CcSEcCtD
Regorafenib—ABCB1—spinal cord—multiple sclerosis	0.000198	0.00192	CbGeAlD
Regorafenib—Body temperature increased—Triamcinolone—multiple sclerosis	0.000197	0.00106	CcSEcCtD
Regorafenib—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000196	0.00106	CcSEcCtD
Regorafenib—Decreased appetite—Betamethasone—multiple sclerosis	0.000196	0.00106	CcSEcCtD
Regorafenib—Decreased appetite—Dexamethasone—multiple sclerosis	0.000196	0.00106	CcSEcCtD
Regorafenib—Nausea—Mitoxantrone—multiple sclerosis	0.000196	0.00105	CcSEcCtD
Regorafenib—Infection—Prednisone—multiple sclerosis	0.000196	0.00105	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000195	0.00105	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000195	0.00105	CcSEcCtD
Regorafenib—Fatigue—Dexamethasone—multiple sclerosis	0.000195	0.00105	CcSEcCtD
Regorafenib—Fatigue—Betamethasone—multiple sclerosis	0.000195	0.00105	CcSEcCtD
Regorafenib—Pain—Dexamethasone—multiple sclerosis	0.000193	0.00104	CcSEcCtD
Regorafenib—Pain—Betamethasone—multiple sclerosis	0.000193	0.00104	CcSEcCtD
Regorafenib—Nervous system disorder—Prednisone—multiple sclerosis	0.000193	0.00104	CcSEcCtD
Regorafenib—Skin disorder—Prednisone—multiple sclerosis	0.000191	0.00103	CcSEcCtD
Regorafenib—Anaemia—Methotrexate—multiple sclerosis	0.000186	0.001	CcSEcCtD
Regorafenib—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000185	0.000993	CcSEcCtD
Regorafenib—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000185	0.000993	CcSEcCtD
Regorafenib—Leukopenia—Methotrexate—multiple sclerosis	0.00018	0.000969	CcSEcCtD
Regorafenib—Asthenia—Triamcinolone—multiple sclerosis	0.000179	0.00096	CcSEcCtD
Regorafenib—Body temperature increased—Dexamethasone—multiple sclerosis	0.000179	0.00096	CcSEcCtD
Regorafenib—Abdominal pain—Dexamethasone—multiple sclerosis	0.000179	0.00096	CcSEcCtD
Regorafenib—Abdominal pain—Betamethasone—multiple sclerosis	0.000179	0.00096	CcSEcCtD
Regorafenib—Body temperature increased—Betamethasone—multiple sclerosis	0.000179	0.00096	CcSEcCtD
Regorafenib—Asthenia—Methylprednisolone—multiple sclerosis	0.000178	0.000958	CcSEcCtD
Regorafenib—Decreased appetite—Prednisone—multiple sclerosis	0.000171	0.000919	CcSEcCtD
Regorafenib—Rash—Prednisolone—multiple sclerosis	0.000171	0.000918	CcSEcCtD
Regorafenib—Dermatitis—Prednisolone—multiple sclerosis	0.000171	0.000917	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.00017	0.000916	CcSEcCtD
Regorafenib—Diarrhoea—Methylprednisolone—multiple sclerosis	0.00017	0.000914	CcSEcCtD
Regorafenib—Fatigue—Prednisone—multiple sclerosis	0.00017	0.000912	CcSEcCtD
Regorafenib—Headache—Prednisolone—multiple sclerosis	0.00017	0.000912	CcSEcCtD
Regorafenib—ABCB1—nervous system—multiple sclerosis	0.000167	0.00162	CbGeAlD
Regorafenib—Infection—Methotrexate—multiple sclerosis	0.000163	0.000878	CcSEcCtD
Regorafenib—Asthenia—Betamethasone—multiple sclerosis	0.000162	0.000871	CcSEcCtD
Regorafenib—Asthenia—Dexamethasone—multiple sclerosis	0.000162	0.000871	CcSEcCtD
Regorafenib—Nervous system disorder—Methotrexate—multiple sclerosis	0.000161	0.000867	CcSEcCtD
Regorafenib—Thrombocytopenia—Methotrexate—multiple sclerosis	0.000161	0.000865	CcSEcCtD
Regorafenib—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000161	0.000865	CcSEcCtD
Regorafenib—Nausea—Prednisolone—multiple sclerosis	0.000161	0.000864	CcSEcCtD
Regorafenib—ABCB1—central nervous system—multiple sclerosis	0.000161	0.00156	CbGeAlD
Regorafenib—Skin disorder—Methotrexate—multiple sclerosis	0.00016	0.000859	CcSEcCtD
Regorafenib—Vomiting—Triamcinolone—multiple sclerosis	0.000158	0.000851	CcSEcCtD
Regorafenib—Vomiting—Methylprednisolone—multiple sclerosis	0.000158	0.000849	CcSEcCtD
Regorafenib—ABCB1—cerebellum—multiple sclerosis	0.000157	0.00153	CbGeAlD
Regorafenib—Rash—Triamcinolone—multiple sclerosis	0.000157	0.000844	CcSEcCtD
Regorafenib—Dermatitis—Triamcinolone—multiple sclerosis	0.000157	0.000843	CcSEcCtD
Regorafenib—Rash—Methylprednisolone—multiple sclerosis	0.000157	0.000842	CcSEcCtD
Regorafenib—Dermatitis—Methylprednisolone—multiple sclerosis	0.000157	0.000841	CcSEcCtD
Regorafenib—Headache—Triamcinolone—multiple sclerosis	0.000156	0.000838	CcSEcCtD
Regorafenib—Headache—Methylprednisolone—multiple sclerosis	0.000156	0.000837	CcSEcCtD
Regorafenib—Body temperature increased—Prednisone—multiple sclerosis	0.000156	0.000836	CcSEcCtD
Regorafenib—Abdominal pain—Prednisone—multiple sclerosis	0.000156	0.000836	CcSEcCtD
Regorafenib—Diarrhoea—Betamethasone—multiple sclerosis	0.000155	0.000831	CcSEcCtD
Regorafenib—Diarrhoea—Dexamethasone—multiple sclerosis	0.000155	0.000831	CcSEcCtD
Regorafenib—Nausea—Triamcinolone—multiple sclerosis	0.000148	0.000795	CcSEcCtD
Regorafenib—Nausea—Methylprednisolone—multiple sclerosis	0.000148	0.000793	CcSEcCtD
Regorafenib—Vomiting—Dexamethasone—multiple sclerosis	0.000144	0.000772	CcSEcCtD
Regorafenib—Vomiting—Betamethasone—multiple sclerosis	0.000144	0.000772	CcSEcCtD
Regorafenib—Decreased appetite—Methotrexate—multiple sclerosis	0.000143	0.000768	CcSEcCtD
Regorafenib—Rash—Dexamethasone—multiple sclerosis	0.000142	0.000766	CcSEcCtD
Regorafenib—Rash—Betamethasone—multiple sclerosis	0.000142	0.000766	CcSEcCtD
Regorafenib—Dermatitis—Dexamethasone—multiple sclerosis	0.000142	0.000765	CcSEcCtD
Regorafenib—Dermatitis—Betamethasone—multiple sclerosis	0.000142	0.000765	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000142	0.000763	CcSEcCtD
Regorafenib—Fatigue—Methotrexate—multiple sclerosis	0.000142	0.000762	CcSEcCtD
Regorafenib—Headache—Betamethasone—multiple sclerosis	0.000142	0.000761	CcSEcCtD
Regorafenib—Headache—Dexamethasone—multiple sclerosis	0.000142	0.000761	CcSEcCtD
Regorafenib—Asthenia—Prednisone—multiple sclerosis	0.000141	0.000759	CcSEcCtD
Regorafenib—Pain—Methotrexate—multiple sclerosis	0.000141	0.000756	CcSEcCtD
Regorafenib—Diarrhoea—Prednisone—multiple sclerosis	0.000135	0.000724	CcSEcCtD
Regorafenib—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000134	0.000723	CcSEcCtD
Regorafenib—Nausea—Dexamethasone—multiple sclerosis	0.000134	0.000721	CcSEcCtD
Regorafenib—Nausea—Betamethasone—multiple sclerosis	0.000134	0.000721	CcSEcCtD
Regorafenib—Abdominal pain—Methotrexate—multiple sclerosis	0.00013	0.000699	CcSEcCtD
Regorafenib—Body temperature increased—Methotrexate—multiple sclerosis	0.00013	0.000699	CcSEcCtD
Regorafenib—ABCB1—brain—multiple sclerosis	0.000128	0.00124	CbGeAlD
Regorafenib—Vomiting—Prednisone—multiple sclerosis	0.000125	0.000672	CcSEcCtD
Regorafenib—Rash—Prednisone—multiple sclerosis	0.000124	0.000667	CcSEcCtD
Regorafenib—Dermatitis—Prednisone—multiple sclerosis	0.000124	0.000666	CcSEcCtD
Regorafenib—Headache—Prednisone—multiple sclerosis	0.000123	0.000663	CcSEcCtD
Regorafenib—Asthenia—Methotrexate—multiple sclerosis	0.000118	0.000634	CcSEcCtD
Regorafenib—Nausea—Prednisone—multiple sclerosis	0.000117	0.000628	CcSEcCtD
Regorafenib—Diarrhoea—Methotrexate—multiple sclerosis	0.000113	0.000605	CcSEcCtD
Regorafenib—Vomiting—Methotrexate—multiple sclerosis	0.000105	0.000562	CcSEcCtD
Regorafenib—Rash—Methotrexate—multiple sclerosis	0.000104	0.000557	CcSEcCtD
Regorafenib—Dermatitis—Methotrexate—multiple sclerosis	0.000104	0.000557	CcSEcCtD
Regorafenib—Headache—Methotrexate—multiple sclerosis	0.000103	0.000554	CcSEcCtD
Regorafenib—Nausea—Methotrexate—multiple sclerosis	9.77e-05	0.000525	CcSEcCtD
Regorafenib—FLT1—Signaling Pathways—MYC—multiple sclerosis	8.65e-06	3.36e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—TGFB1—multiple sclerosis	8.63e-06	3.35e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—POMC—multiple sclerosis	8.56e-06	3.33e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	8.53e-06	3.32e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—APOE—multiple sclerosis	8.53e-06	3.32e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—APOE—multiple sclerosis	8.51e-06	3.31e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—POMC—multiple sclerosis	8.48e-06	3.3e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—IFNG—multiple sclerosis	8.47e-06	3.29e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CD86—multiple sclerosis	8.47e-06	3.29e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—MAPK1—multiple sclerosis	8.46e-06	3.29e-05	CbGpPWpGaD
Regorafenib—FGFR1—Innate Immune System—IL6—multiple sclerosis	8.46e-06	3.29e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Innate Immune System—IL6—multiple sclerosis	8.43e-06	3.28e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CCR5—multiple sclerosis	8.42e-06	3.28e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—IL1B—multiple sclerosis	8.41e-06	3.27e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—CD4—multiple sclerosis	8.41e-06	3.27e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—APOE—multiple sclerosis	8.4e-06	3.26e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—APOE—multiple sclerosis	8.4e-06	3.26e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—IL1B—multiple sclerosis	8.39e-06	3.26e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—CD4—multiple sclerosis	8.39e-06	3.26e-05	CbGpPWpGaD
Regorafenib—ABL1—Developmental Biology—IL6—multiple sclerosis	8.38e-06	3.26e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—IL2—multiple sclerosis	8.38e-06	3.26e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—CCL2—multiple sclerosis	8.38e-06	3.26e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—IL2—multiple sclerosis	8.36e-06	3.25e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—TYK2—multiple sclerosis	8.35e-06	3.25e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CCL5—multiple sclerosis	8.34e-06	3.24e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—IL2RA—multiple sclerosis	8.3e-06	3.23e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—CCL2—multiple sclerosis	8.3e-06	3.23e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GPC5—multiple sclerosis	8.29e-06	3.22e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—CD80—multiple sclerosis	8.27e-06	3.22e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—IFNG—multiple sclerosis	8.26e-06	3.21e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—STAT3—multiple sclerosis	8.24e-06	3.2e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—CD4—multiple sclerosis	8.18e-06	3.18e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—CD80—multiple sclerosis	8.13e-06	3.16e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	8.08e-06	3.14e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—TYK2—multiple sclerosis	8.06e-06	3.14e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—CD4—multiple sclerosis	7.97e-06	3.1e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—POMC—multiple sclerosis	7.86e-06	3.06e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—IL2—multiple sclerosis	7.79e-06	3.03e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	7.78e-06	3.02e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—POMC—multiple sclerosis	7.72e-06	3e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—SPP1—multiple sclerosis	7.72e-06	3e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—CD80—multiple sclerosis	7.71e-06	3e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—CD80—multiple sclerosis	7.69e-06	2.99e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—CCL2—multiple sclerosis	7.69e-06	2.99e-05	CbGpPWpGaD
Regorafenib—RAF1—Developmental Biology—IL6—multiple sclerosis	7.67e-06	2.98e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—APOE—multiple sclerosis	7.66e-06	2.98e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	7.61e-06	2.96e-05	CbGpPWpGaD
Regorafenib—MAPK11—Gene Expression—MYC—multiple sclerosis	7.61e-06	2.96e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—TYK2—multiple sclerosis	7.61e-06	2.96e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Innate Immune System—IL6—multiple sclerosis	7.6e-06	2.95e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—STAT3—multiple sclerosis	7.56e-06	2.94e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—IL1B—multiple sclerosis	7.56e-06	2.94e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—CD4—multiple sclerosis	7.56e-06	2.94e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—CCL2—multiple sclerosis	7.55e-06	2.94e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—IFNG—multiple sclerosis	7.55e-06	2.94e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—TYK2—multiple sclerosis	7.54e-06	2.93e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—STAT3—multiple sclerosis	7.54e-06	2.93e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—IL2—multiple sclerosis	7.53e-06	2.93e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CCR5—multiple sclerosis	7.51e-06	2.92e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—MAPK1—multiple sclerosis	7.49e-06	2.91e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—TYK2—multiple sclerosis	7.45e-06	2.89e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—STAT3—multiple sclerosis	7.43e-06	2.89e-05	CbGpPWpGaD
Regorafenib—ABL1—Innate Immune System—IL6—multiple sclerosis	7.4e-06	2.88e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IL2RA—multiple sclerosis	7.4e-06	2.88e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—MMP9—multiple sclerosis	7.37e-06	2.87e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—IL1B—multiple sclerosis	7.36e-06	2.86e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—IL2—multiple sclerosis	7.36e-06	2.86e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—BCHE—multiple sclerosis	7.35e-06	2.86e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—IL2—multiple sclerosis	7.34e-06	2.86e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—IL2—multiple sclerosis	7.34e-06	2.85e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—POMC—multiple sclerosis	7.33e-06	2.85e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—POMC—multiple sclerosis	7.31e-06	2.84e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—CD4—multiple sclerosis	7.29e-06	2.84e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—POMC—multiple sclerosis	7.22e-06	2.8e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—POMC—multiple sclerosis	7.22e-06	2.8e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—CCL2—multiple sclerosis	7.17e-06	2.79e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—CCL2—multiple sclerosis	7.15e-06	2.78e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—APOE—multiple sclerosis	7.13e-06	2.77e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—STAT3—multiple sclerosis	7.05e-06	2.74e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—STAT3—multiple sclerosis	7.03e-06	2.73e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—MYC—multiple sclerosis	7e-06	2.72e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—TGFB1—multiple sclerosis	6.99e-06	2.72e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—TYK2—multiple sclerosis	6.98e-06	2.72e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—STAT3—multiple sclerosis	6.98e-06	2.71e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—MMP9—multiple sclerosis	6.97e-06	2.71e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	6.94e-06	2.7e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	6.94e-06	2.7e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CD80—multiple sclerosis	6.93e-06	2.69e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—MAPK1—multiple sclerosis	6.88e-06	2.67e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—RRM1—multiple sclerosis	6.87e-06	2.67e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—TYK2—multiple sclerosis	6.86e-06	2.67e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—STAT3—multiple sclerosis	6.86e-06	2.67e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—MAPK1—multiple sclerosis	6.85e-06	2.66e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—APOE—multiple sclerosis	6.83e-06	2.66e-05	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—IL6—multiple sclerosis	6.77e-06	2.63e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—MAPK1—multiple sclerosis	6.75e-06	2.63e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—IL1B—multiple sclerosis	6.74e-06	2.62e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—CD4—multiple sclerosis	6.73e-06	2.62e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—IL2—multiple sclerosis	6.71e-06	2.61e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—POMC—multiple sclerosis	6.58e-06	2.56e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—ALB—multiple sclerosis	6.58e-06	2.56e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—ALB—multiple sclerosis	6.58e-06	2.56e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—BCHE—multiple sclerosis	6.56e-06	2.55e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—STAT3—multiple sclerosis	6.56e-06	2.55e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—TYK2—multiple sclerosis	6.51e-06	2.53e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—STAT3—multiple sclerosis	6.51e-06	2.53e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—IL6—multiple sclerosis	6.5e-06	2.53e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—TYK2—multiple sclerosis	6.49e-06	2.52e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—STAT3—multiple sclerosis	6.49e-06	2.52e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—MYC—multiple sclerosis	6.49e-06	2.52e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—TGFB1—multiple sclerosis	6.47e-06	2.52e-05	CbGpPWpGaD
Regorafenib—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	6.44e-06	2.5e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CCL2—multiple sclerosis	6.44e-06	2.5e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—MAPK1—multiple sclerosis	6.41e-06	2.49e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—BCHE—multiple sclerosis	6.4e-06	2.49e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—MAPK1—multiple sclerosis	6.39e-06	2.49e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—MYC—multiple sclerosis	6.37e-06	2.48e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—TGFB1—multiple sclerosis	6.36e-06	2.47e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—MAPK1—multiple sclerosis	6.35e-06	2.47e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—STAT3—multiple sclerosis	6.34e-06	2.46e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—IL2—multiple sclerosis	6.33e-06	2.46e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	6.33e-06	2.46e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—IL2—multiple sclerosis	6.27e-06	2.44e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—MAPK1—multiple sclerosis	6.24e-06	2.42e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—STAT3—multiple sclerosis	6.19e-06	2.41e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CD80—multiple sclerosis	6.18e-06	2.4e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—STAT3—multiple sclerosis	6.17e-06	2.4e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—POMC—multiple sclerosis	6.12e-06	2.38e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—MYC—multiple sclerosis	6.09e-06	2.37e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—TGFB1—multiple sclerosis	6.08e-06	2.36e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—MYC—multiple sclerosis	6.05e-06	2.35e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—TGFB1—multiple sclerosis	6.03e-06	2.35e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—MYC—multiple sclerosis	6.03e-06	2.35e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—TGFB1—multiple sclerosis	6.02e-06	2.34e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—MMP9—multiple sclerosis	5.99e-06	2.33e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—BCHE—multiple sclerosis	5.98e-06	2.33e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—MAPK1—multiple sclerosis	5.96e-06	2.32e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—MMP9—multiple sclerosis	5.94e-06	2.31e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—MAPK1—multiple sclerosis	5.92e-06	2.3e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—MAPK1—multiple sclerosis	5.9e-06	2.29e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—POMC—multiple sclerosis	5.87e-06	2.28e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—TYK2—multiple sclerosis	5.85e-06	2.27e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—STAT3—multiple sclerosis	5.85e-06	2.27e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—IL2—multiple sclerosis	5.81e-06	2.26e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—MAPK1—multiple sclerosis	5.76e-06	2.24e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—MYC—multiple sclerosis	5.76e-06	2.24e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—IL6—multiple sclerosis	5.76e-06	2.24e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—TGFB1—multiple sclerosis	5.74e-06	2.23e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CCL2—multiple sclerosis	5.74e-06	2.23e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—IL2—multiple sclerosis	5.71e-06	2.22e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—STAT3—multiple sclerosis	5.65e-06	2.2e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—MAPK1—multiple sclerosis	5.63e-06	2.19e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—MAPK1—multiple sclerosis	5.62e-06	2.18e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—MAPK1—multiple sclerosis	5.61e-06	2.18e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—ALB—multiple sclerosis	5.58e-06	2.17e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—MMP9—multiple sclerosis	5.5e-06	2.14e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—MYC—multiple sclerosis	5.44e-06	2.11e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—TGFB1—multiple sclerosis	5.42e-06	2.11e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—IL2—multiple sclerosis	5.42e-06	2.11e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—IL2—multiple sclerosis	5.4e-06	2.1e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—MMP9—multiple sclerosis	5.4e-06	2.1e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—STAT3—multiple sclerosis	5.33e-06	2.07e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—MAPK1—multiple sclerosis	5.32e-06	2.07e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—IL6—multiple sclerosis	5.28e-06	2.05e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—STAT3—multiple sclerosis	5.28e-06	2.05e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—IL6—multiple sclerosis	5.26e-06	2.05e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—APOE—multiple sclerosis	5.22e-06	2.03e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—TYK2—multiple sclerosis	5.21e-06	2.03e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—STAT3—multiple sclerosis	5.21e-06	2.03e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—IL6—multiple sclerosis	5.19e-06	2.02e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—MAPK1—multiple sclerosis	5.13e-06	2e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—MMP9—multiple sclerosis	5.13e-06	1.99e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—MMP9—multiple sclerosis	5.11e-06	1.99e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—MYC—multiple sclerosis	4.95e-06	1.92e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—TGFB1—multiple sclerosis	4.94e-06	1.92e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—IL6—multiple sclerosis	4.92e-06	1.91e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—IL6—multiple sclerosis	4.91e-06	1.91e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—MYC—multiple sclerosis	4.9e-06	1.91e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—TGFB1—multiple sclerosis	4.89e-06	1.9e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—STAT3—multiple sclerosis	4.89e-06	1.9e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—IL6—multiple sclerosis	4.88e-06	1.9e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—IL2—multiple sclerosis	4.87e-06	1.89e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—MYC—multiple sclerosis	4.84e-06	1.88e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—MAPK1—multiple sclerosis	4.84e-06	1.88e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—TGFB1—multiple sclerosis	4.83e-06	1.88e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—STAT3—multiple sclerosis	4.8e-06	1.87e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—MAPK1—multiple sclerosis	4.8e-06	1.86e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—IL6—multiple sclerosis	4.79e-06	1.86e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—MAPK1—multiple sclerosis	4.74e-06	1.84e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MMP9—multiple sclerosis	4.61e-06	1.79e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—IL6—multiple sclerosis	4.58e-06	1.78e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—STAT3—multiple sclerosis	4.56e-06	1.77e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—IL6—multiple sclerosis	4.55e-06	1.77e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—STAT3—multiple sclerosis	4.55e-06	1.77e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—MYC—multiple sclerosis	4.54e-06	1.77e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—IL6—multiple sclerosis	4.54e-06	1.76e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—TGFB1—multiple sclerosis	4.53e-06	1.76e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—POMC—multiple sclerosis	4.49e-06	1.74e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—MYC—multiple sclerosis	4.46e-06	1.74e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—TGFB1—multiple sclerosis	4.45e-06	1.73e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—MAPK1—multiple sclerosis	4.45e-06	1.73e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—IL6—multiple sclerosis	4.43e-06	1.72e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—APOE—multiple sclerosis	4.42e-06	1.72e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—MAPK1—multiple sclerosis	4.37e-06	1.7e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IL2—multiple sclerosis	4.34e-06	1.69e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—IL6—multiple sclerosis	4.33e-06	1.68e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—IL6—multiple sclerosis	4.32e-06	1.68e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—IL6—multiple sclerosis	4.31e-06	1.68e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—MYC—multiple sclerosis	4.24e-06	1.65e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—TGFB1—multiple sclerosis	4.23e-06	1.64e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—MYC—multiple sclerosis	4.22e-06	1.64e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—TGFB1—multiple sclerosis	4.21e-06	1.64e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—MAPK1—multiple sclerosis	4.14e-06	1.61e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—MAPK1—multiple sclerosis	4.13e-06	1.61e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MMP9—multiple sclerosis	4.11e-06	1.6e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—STAT3—multiple sclerosis	4.1e-06	1.59e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—ALB—multiple sclerosis	4.09e-06	1.59e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—IL6—multiple sclerosis	4.09e-06	1.59e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—APOE—multiple sclerosis	3.95e-06	1.53e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—BCHE—multiple sclerosis	3.95e-06	1.53e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—IL6—multiple sclerosis	3.94e-06	1.53e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—APOE—multiple sclerosis	3.85e-06	1.5e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MYC—multiple sclerosis	3.81e-06	1.48e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—POMC—multiple sclerosis	3.8e-06	1.48e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—TGFB1—multiple sclerosis	3.8e-06	1.48e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MAPK1—multiple sclerosis	3.72e-06	1.45e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—IL6—multiple sclerosis	3.72e-06	1.45e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—IL6—multiple sclerosis	3.69e-06	1.43e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—STAT3—multiple sclerosis	3.65e-06	1.42e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—IL6—multiple sclerosis	3.64e-06	1.42e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—APOE—multiple sclerosis	3.6e-06	1.4e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—ALB—multiple sclerosis	3.46e-06	1.35e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—IL6—multiple sclerosis	3.42e-06	1.33e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MYC—multiple sclerosis	3.39e-06	1.32e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—POMC—multiple sclerosis	3.39e-06	1.32e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—TGFB1—multiple sclerosis	3.38e-06	1.32e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—IL6—multiple sclerosis	3.36e-06	1.3e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MAPK1—multiple sclerosis	3.32e-06	1.29e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—POMC—multiple sclerosis	3.31e-06	1.29e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—IL6—multiple sclerosis	3.18e-06	1.24e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—IL6—multiple sclerosis	3.18e-06	1.23e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—POMC—multiple sclerosis	3.09e-06	1.2e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—ALB—multiple sclerosis	3.09e-06	1.2e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—ALB—multiple sclerosis	3.02e-06	1.17e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—IL6—multiple sclerosis	2.86e-06	1.11e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—ALB—multiple sclerosis	2.82e-06	1.1e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IL6—multiple sclerosis	2.55e-06	9.91e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—APOE—multiple sclerosis	2.37e-06	9.23e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—POMC—multiple sclerosis	2.04e-06	7.93e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ALB—multiple sclerosis	1.86e-06	7.23e-06	CbGpPWpGaD
